| __timestamp | Alnylam Pharmaceuticals, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 79383000 |
| Thursday, January 1, 2015 | 60610000 | 108402000 |
| Friday, January 1, 2016 | 89354000 | 46928000 |
| Sunday, January 1, 2017 | 199365000 | 74959000 |
| Monday, January 1, 2018 | 382359000 | 79716000 |
| Tuesday, January 1, 2019 | 479005000 | 74669000 |
| Wednesday, January 1, 2020 | 588420000 | 59040000 |
| Friday, January 1, 2021 | 620639000 | 77417000 |
| Saturday, January 1, 2022 | 770658000 | 91473000 |
| Sunday, January 1, 2023 | 795646000 | 94314000 |
| Monday, January 1, 2024 | 975526000 |
Cracking the code
In the competitive world of biotechnology, operational efficiency is key. Alnylam Pharmaceuticals, Inc. and MannKind Corporation, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Alnylam's SG&A expenses have surged by over 1,600%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, MannKind's expenses have remained relatively stable, with a modest increase of about 19% over the same period. This divergence highlights Alnylam's strategic focus on scaling operations, while MannKind maintains a more conservative approach. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning. Investors and industry analysts should keep a close eye on how these trends impact future growth and profitability.
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation